nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—bone cancer	0.712	0.856	CbGaD
Irbesartan—CYP3A4—bone cancer	0.12	0.144	CbGaD
Irbesartan—Tasosartan—CYP3A4—bone cancer	0.00074	0.703	CrCbGaD
Irbesartan—Losartan—CYP3A4—bone cancer	0.000313	0.297	CrCbGaD
Irbesartan—Hyperglycaemia—Epirubicin—bone cancer	0.000154	0.00189	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—bone cancer	0.000153	0.00189	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—bone cancer	0.000153	0.00189	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—bone cancer	0.000153	0.00188	CcSEcCtD
Irbesartan—Pneumonia—Epirubicin—bone cancer	0.000153	0.00188	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—bone cancer	0.000151	0.00186	CcSEcCtD
Irbesartan—Renal failure—Epirubicin—bone cancer	0.000149	0.00184	CcSEcCtD
Irbesartan—Body temperature increased—Cisplatin—bone cancer	0.000149	0.00183	CcSEcCtD
Irbesartan—Jaundice—Epirubicin—bone cancer	0.000148	0.00182	CcSEcCtD
Irbesartan—Conjunctivitis—Epirubicin—bone cancer	0.000148	0.00182	CcSEcCtD
Irbesartan—Urinary tract infection—Epirubicin—bone cancer	0.000148	0.00182	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—bone cancer	0.000147	0.00181	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000146	0.0018	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—bone cancer	0.000146	0.00179	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—bone cancer	0.000145	0.00178	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—bone cancer	0.000144	0.00177	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—bone cancer	0.000144	0.00177	CcSEcCtD
Irbesartan—Hepatobiliary disease—Epirubicin—bone cancer	0.000144	0.00177	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—bone cancer	0.000143	0.00176	CcSEcCtD
Irbesartan—Epistaxis—Epirubicin—bone cancer	0.000143	0.00176	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—bone cancer	0.000143	0.00176	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—bone cancer	0.000142	0.00175	CcSEcCtD
Irbesartan—JUN—Apoptosis—MDM2—bone cancer	0.000142	0.00165	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—GRM4—bone cancer	0.000142	0.00165	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—RGS1—bone cancer	0.000142	0.00165	CbGpPWpGaD
Irbesartan—Agranulocytosis—Epirubicin—bone cancer	0.000142	0.00174	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—BRAF—bone cancer	0.000142	0.00165	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—BRAF—bone cancer	0.000142	0.00165	CbGpPWpGaD
Irbesartan—Pneumonia—Doxorubicin—bone cancer	0.000141	0.00174	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—bone cancer	0.00014	0.00173	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—RB1—bone cancer	0.000139	0.00162	CbGpPWpGaD
Irbesartan—Hypersensitivity—Cisplatin—bone cancer	0.000139	0.00171	CcSEcCtD
Irbesartan—JUN—AP-1 transcription factor network—MMP9—bone cancer	0.000139	0.00161	CbGpPWpGaD
Irbesartan—Bradycardia—Epirubicin—bone cancer	0.000139	0.00171	CcSEcCtD
Irbesartan—Renal failure—Doxorubicin—bone cancer	0.000138	0.0017	CcSEcCtD
Irbesartan—JUN—ErbB Signaling Pathway—EGFR—bone cancer	0.000138	0.00161	CbGpPWpGaD
Irbesartan—Jaundice—Doxorubicin—bone cancer	0.000137	0.00168	CcSEcCtD
Irbesartan—Rhinitis—Epirubicin—bone cancer	0.000137	0.00168	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—bone cancer	0.000137	0.00168	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—bone cancer	0.000137	0.00168	CcSEcCtD
Irbesartan—Hepatitis—Epirubicin—bone cancer	0.000136	0.00168	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—bone cancer	0.000136	0.00167	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—EZH2—bone cancer	0.000136	0.00158	CbGpPWpGaD
Irbesartan—Hypoaesthesia—Epirubicin—bone cancer	0.000136	0.00167	CcSEcCtD
Irbesartan—JUN—Androgen receptor signaling pathway—MDM2—bone cancer	0.000135	0.00158	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—GRM1—bone cancer	0.000135	0.00157	CbGpPWpGaD
Irbesartan—Asthenia—Cisplatin—bone cancer	0.000135	0.00166	CcSEcCtD
Irbesartan—Pharyngitis—Epirubicin—bone cancer	0.000135	0.00166	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—bone cancer	0.000135	0.00166	CcSEcCtD
Irbesartan—Urinary tract disorder—Epirubicin—bone cancer	0.000135	0.00166	CcSEcCtD
Irbesartan—Oedema peripheral—Epirubicin—bone cancer	0.000134	0.00165	CcSEcCtD
Irbesartan—JUN—Pre-NOTCH Expression and Processing—TP53—bone cancer	0.000134	0.00156	CbGpPWpGaD
Irbesartan—Connective tissue disorder—Epirubicin—bone cancer	0.000134	0.00165	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000134	0.00156	CbGpPWpGaD
Irbesartan—Urethral disorder—Epirubicin—bone cancer	0.000134	0.00164	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—MET—bone cancer	0.000133	0.00155	CbGpPWpGaD
Irbesartan—Hepatobiliary disease—Doxorubicin—bone cancer	0.000133	0.00163	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—bone cancer	0.000133	0.00163	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—SMO—bone cancer	0.000132	0.00154	CbGpPWpGaD
Irbesartan—Angiopathy—Methotrexate—bone cancer	0.000132	0.00163	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—bone cancer	0.000132	0.00162	CcSEcCtD
Irbesartan—Visual impairment—Epirubicin—bone cancer	0.000131	0.00162	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—bone cancer	0.000131	0.00161	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—bone cancer	0.000131	0.00161	CcSEcCtD
Irbesartan—Chills—Methotrexate—bone cancer	0.000131	0.00161	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—IGF1R—bone cancer	0.000129	0.0015	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—NDUFA12—bone cancer	0.000129	0.0015	CbGpPWpGaD
Irbesartan—Diarrhoea—Cisplatin—bone cancer	0.000129	0.00159	CcSEcCtD
Irbesartan—Bradycardia—Doxorubicin—bone cancer	0.000128	0.00158	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—MET—bone cancer	0.000127	0.00148	CbGpPWpGaD
Irbesartan—Tinnitus—Epirubicin—bone cancer	0.000127	0.00156	CcSEcCtD
Irbesartan—Erythema—Methotrexate—bone cancer	0.000127	0.00156	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—bone cancer	0.000127	0.00156	CcSEcCtD
Irbesartan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000127	0.00147	CbGpPWpGaD
Irbesartan—Flushing—Epirubicin—bone cancer	0.000126	0.00156	CcSEcCtD
Irbesartan—Cardiac disorder—Epirubicin—bone cancer	0.000126	0.00156	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—bone cancer	0.000126	0.00156	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—bone cancer	0.000126	0.00155	CcSEcCtD
Irbesartan—Hypoaesthesia—Doxorubicin—bone cancer	0.000125	0.00154	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—bone cancer	0.000125	0.00154	CcSEcCtD
Irbesartan—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000125	0.00145	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000125	0.00145	CbGpPWpGaD
Irbesartan—Urinary tract disorder—Doxorubicin—bone cancer	0.000125	0.00153	CcSEcCtD
Irbesartan—Oedema peripheral—Doxorubicin—bone cancer	0.000124	0.00153	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—bone cancer	0.000124	0.00153	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—bone cancer	0.000124	0.00152	CcSEcCtD
Irbesartan—Angiopathy—Epirubicin—bone cancer	0.000124	0.00152	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—bone cancer	0.000124	0.00152	CcSEcCtD
Irbesartan—JUN—PDGFR-beta signaling pathway—BRAF—bone cancer	0.000123	0.00143	CbGpPWpGaD
Irbesartan—Immune system disorder—Epirubicin—bone cancer	0.000123	0.00151	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—GRM1—bone cancer	0.000123	0.00143	CbGpPWpGaD
Irbesartan—Mediastinal disorder—Epirubicin—bone cancer	0.000123	0.00151	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—RGS1—bone cancer	0.000123	0.00143	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—GRM4—bone cancer	0.000123	0.00143	CbGpPWpGaD
Irbesartan—Chills—Epirubicin—bone cancer	0.000122	0.0015	CcSEcCtD
Irbesartan—Arrhythmia—Epirubicin—bone cancer	0.000122	0.0015	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—bone cancer	0.000122	0.0015	CcSEcCtD
Irbesartan—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000121	0.00141	CbGpPWpGaD
Irbesartan—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000121	0.00141	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—EGFR—bone cancer	0.000121	0.0014	CbGpPWpGaD
Irbesartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00012	0.0014	CbGpPWpGaD
Irbesartan—Vomiting—Cisplatin—bone cancer	0.00012	0.00148	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00012	0.00139	CbGpPWpGaD
Irbesartan—JUN—Copper homeostasis—TP53—bone cancer	0.000119	0.00139	CbGpPWpGaD
Irbesartan—Vision blurred—Methotrexate—bone cancer	0.000119	0.00147	CcSEcCtD
Irbesartan—Rash—Cisplatin—bone cancer	0.000119	0.00146	CcSEcCtD
Irbesartan—Dermatitis—Cisplatin—bone cancer	0.000119	0.00146	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—MDM2—bone cancer	0.000119	0.00138	CbGpPWpGaD
Irbesartan—Malnutrition—Epirubicin—bone cancer	0.000119	0.00146	CcSEcCtD
Irbesartan—Erythema—Epirubicin—bone cancer	0.000119	0.00146	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—bone cancer	0.000118	0.00145	CcSEcCtD
Irbesartan—JUN—AGE/RAGE pathway—EGFR—bone cancer	0.000118	0.00137	CbGpPWpGaD
Irbesartan—Tinnitus—Doxorubicin—bone cancer	0.000118	0.00145	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—bone cancer	0.000117	0.00144	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—bone cancer	0.000117	0.00144	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—bone cancer	0.000117	0.00144	CcSEcCtD
Irbesartan—Flatulence—Epirubicin—bone cancer	0.000117	0.00144	CcSEcCtD
Irbesartan—Tension—Epirubicin—bone cancer	0.000116	0.00143	CcSEcCtD
Irbesartan—Dysgeusia—Epirubicin—bone cancer	0.000116	0.00143	CcSEcCtD
Irbesartan—JUN—ErbB Signaling Pathway—TP53—bone cancer	0.000116	0.00135	CbGpPWpGaD
Irbesartan—Nervousness—Epirubicin—bone cancer	0.000115	0.00142	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—MDM2—bone cancer	0.000115	0.00134	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—EGFR—bone cancer	0.000115	0.00134	CbGpPWpGaD
Irbesartan—Angiopathy—Doxorubicin—bone cancer	0.000114	0.00141	CcSEcCtD
Irbesartan—Malaise—Methotrexate—bone cancer	0.000114	0.00141	CcSEcCtD
Irbesartan—Muscle spasms—Epirubicin—bone cancer	0.000114	0.0014	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—bone cancer	0.000114	0.0014	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—bone cancer	0.000114	0.0014	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—bone cancer	0.000114	0.0014	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—bone cancer	0.000113	0.0014	CcSEcCtD
Irbesartan—Chills—Doxorubicin—bone cancer	0.000113	0.00139	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—bone cancer	0.000113	0.00139	CcSEcCtD
Irbesartan—Nausea—Cisplatin—bone cancer	0.000112	0.00138	CcSEcCtD
Irbesartan—Vision blurred—Epirubicin—bone cancer	0.000112	0.00138	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—RGS1—bone cancer	0.000111	0.00129	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GRM4—bone cancer	0.000111	0.00129	CbGpPWpGaD
Irbesartan—Cough—Methotrexate—bone cancer	0.000111	0.00136	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—RB1—bone cancer	0.000111	0.00129	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Epirubicin—bone cancer	0.00011	0.00135	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—bone cancer	0.00011	0.00135	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—bone cancer	0.00011	0.00135	CcSEcCtD
Irbesartan—Anaemia—Epirubicin—bone cancer	0.00011	0.00135	CcSEcCtD
Irbesartan—Agitation—Epirubicin—bone cancer	0.000109	0.00134	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—bone cancer	0.000108	0.00133	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—bone cancer	0.000108	0.00133	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—bone cancer	0.000108	0.00133	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—bone cancer	0.000108	0.00133	CcSEcCtD
Irbesartan—Tension—Doxorubicin—bone cancer	0.000108	0.00133	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—bone cancer	0.000108	0.00132	CcSEcCtD
Irbesartan—JUN—Oxidative Stress Induced Senescence—MDM2—bone cancer	0.000107	0.00125	CbGpPWpGaD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000107	0.00132	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—NT5C3A—bone cancer	0.000107	0.00125	CbGpPWpGaD
Irbesartan—Malaise—Epirubicin—bone cancer	0.000107	0.00132	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—bone cancer	0.000107	0.00131	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—bone cancer	0.000107	0.00131	CcSEcCtD
Irbesartan—Vertigo—Epirubicin—bone cancer	0.000107	0.00131	CcSEcCtD
Irbesartan—Syncope—Epirubicin—bone cancer	0.000106	0.00131	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—GRM1—bone cancer	0.000106	0.00124	CbGpPWpGaD
Irbesartan—Leukopenia—Epirubicin—bone cancer	0.000106	0.00131	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—MMP2—bone cancer	0.000106	0.00123	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000106	0.00123	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—GSTP1—bone cancer	0.000106	0.00123	CbGpPWpGaD
Irbesartan—Muscle spasms—Doxorubicin—bone cancer	0.000106	0.0013	CcSEcCtD
Irbesartan—Loss of consciousness—Epirubicin—bone cancer	0.000104	0.00128	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000104	0.00121	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000104	0.00121	CbGpPWpGaD
Irbesartan—Cough—Epirubicin—bone cancer	0.000104	0.00127	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—bone cancer	0.000103	0.00127	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—bone cancer	0.000103	0.00127	CcSEcCtD
Irbesartan—Infection—Methotrexate—bone cancer	0.000103	0.00126	CcSEcCtD
Irbesartan—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000103	0.00119	CbGpPWpGaD
Irbesartan—Hypertension—Epirubicin—bone cancer	0.000102	0.00126	CcSEcCtD
Irbesartan—Ill-defined disorder—Doxorubicin—bone cancer	0.000102	0.00125	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—bone cancer	0.000101	0.00125	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—bone cancer	0.000101	0.00125	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—CDK4—bone cancer	0.000101	0.00118	CbGpPWpGaD
Irbesartan—Thrombocytopenia—Methotrexate—bone cancer	0.000101	0.00125	CcSEcCtD
Irbesartan—Myalgia—Epirubicin—bone cancer	0.000101	0.00124	CcSEcCtD
Irbesartan—Chest pain—Epirubicin—bone cancer	0.000101	0.00124	CcSEcCtD
Irbesartan—Arthralgia—Epirubicin—bone cancer	0.000101	0.00124	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—bone cancer	0.000101	0.00124	CcSEcCtD
Irbesartan—Anxiety—Epirubicin—bone cancer	0.000101	0.00124	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—bone cancer	0.000101	0.00124	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.0001	0.00123	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—BRAF—bone cancer	0.0001	0.00116	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Methotrexate—bone cancer	0.0001	0.00123	CcSEcCtD
Irbesartan—Discomfort—Epirubicin—bone cancer	9.98e-05	0.00123	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—MET—bone cancer	9.96e-05	0.00116	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KIT—bone cancer	9.93e-05	0.00115	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	9.92e-05	0.00115	CbGpPWpGaD
Irbesartan—Malaise—Doxorubicin—bone cancer	9.9e-05	0.00122	CcSEcCtD
Irbesartan—Dry mouth—Epirubicin—bone cancer	9.88e-05	0.00122	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—bone cancer	9.86e-05	0.00121	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—bone cancer	9.86e-05	0.00121	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—bone cancer	9.85e-05	0.00121	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—bone cancer	9.83e-05	0.00121	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—BRAF—bone cancer	9.73e-05	0.00113	CbGpPWpGaD
Irbesartan—Anaphylactic shock—Epirubicin—bone cancer	9.68e-05	0.00119	CcSEcCtD
Irbesartan—Oedema—Epirubicin—bone cancer	9.68e-05	0.00119	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—bone cancer	9.67e-05	0.00119	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—GRM1—bone cancer	9.65e-05	0.00112	CbGpPWpGaD
Irbesartan—Loss of consciousness—Doxorubicin—bone cancer	9.65e-05	0.00119	CcSEcCtD
Irbesartan—Infection—Epirubicin—bone cancer	9.62e-05	0.00118	CcSEcCtD
Irbesartan—Cough—Doxorubicin—bone cancer	9.58e-05	0.00118	CcSEcCtD
Irbesartan—Shock—Epirubicin—bone cancer	9.53e-05	0.00117	CcSEcCtD
Irbesartan—JUN—Circadian rythm related genes—CDK4—bone cancer	9.52e-05	0.00111	CbGpPWpGaD
Irbesartan—Nervous system disorder—Epirubicin—bone cancer	9.5e-05	0.00117	CcSEcCtD
Irbesartan—Thrombocytopenia—Epirubicin—bone cancer	9.48e-05	0.00117	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—bone cancer	9.48e-05	0.00117	CcSEcCtD
Irbesartan—Tachycardia—Epirubicin—bone cancer	9.45e-05	0.00116	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—MDM2—bone cancer	9.43e-05	0.0011	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Methotrexate—bone cancer	9.43e-05	0.00116	CcSEcCtD
Irbesartan—JUN—AP-1 transcription factor network—TP53—bone cancer	9.42e-05	0.0011	CbGpPWpGaD
Irbesartan—Skin disorder—Epirubicin—bone cancer	9.41e-05	0.00116	CcSEcCtD
Irbesartan—Hyperhidrosis—Epirubicin—bone cancer	9.36e-05	0.00115	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—bone cancer	9.35e-05	0.00115	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—bone cancer	9.35e-05	0.00115	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—bone cancer	9.35e-05	0.00115	CcSEcCtD
Irbesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	9.34e-05	0.00109	CbGpPWpGaD
Irbesartan—Anxiety—Doxorubicin—bone cancer	9.31e-05	0.00115	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—bone cancer	9.29e-05	0.00114	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	9.28e-05	0.00114	CcSEcCtD
Irbesartan—JUN—Androgen receptor signaling pathway—EGFR—bone cancer	9.26e-05	0.00108	CbGpPWpGaD
Irbesartan—Discomfort—Doxorubicin—bone cancer	9.23e-05	0.00114	CcSEcCtD
Irbesartan—Anorexia—Epirubicin—bone cancer	9.23e-05	0.00114	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—bone cancer	9.22e-05	0.00113	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	9.2e-05	0.00107	CbGpPWpGaD
Irbesartan—Somnolence—Methotrexate—bone cancer	9.2e-05	0.00113	CcSEcCtD
Irbesartan—Dry mouth—Doxorubicin—bone cancer	9.14e-05	0.00112	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—bone cancer	9.11e-05	0.00112	CcSEcCtD
Irbesartan—Hypotension—Epirubicin—bone cancer	9.05e-05	0.00111	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—bone cancer	8.99e-05	0.00111	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—bone cancer	8.96e-05	0.0011	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—bone cancer	8.96e-05	0.0011	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—bone cancer	8.93e-05	0.0011	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—bone cancer	8.92e-05	0.0011	CcSEcCtD
Irbesartan—Infection—Doxorubicin—bone cancer	8.9e-05	0.0011	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—MDM2—bone cancer	8.88e-05	0.00103	CbGpPWpGaD
Irbesartan—Pain—Methotrexate—bone cancer	8.85e-05	0.00109	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Epirubicin—bone cancer	8.82e-05	0.00109	CcSEcCtD
Irbesartan—Shock—Doxorubicin—bone cancer	8.81e-05	0.00108	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—BRAF—bone cancer	8.81e-05	0.00102	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—RB1—bone cancer	8.81e-05	0.00102	CbGpPWpGaD
Irbesartan—Nervous system disorder—Doxorubicin—bone cancer	8.79e-05	0.00108	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—bone cancer	8.77e-05	0.00108	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—bone cancer	8.74e-05	0.00108	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—GNA11—bone cancer	8.73e-05	0.00101	CbGpPWpGaD
Irbesartan—Skin disorder—Doxorubicin—bone cancer	8.7e-05	0.00107	CcSEcCtD
Irbesartan—Paraesthesia—Epirubicin—bone cancer	8.7e-05	0.00107	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—SMO—bone cancer	8.67e-05	0.00101	CbGpPWpGaD
Irbesartan—Hyperhidrosis—Doxorubicin—bone cancer	8.66e-05	0.00107	CcSEcCtD
Irbesartan—Dyspnoea—Epirubicin—bone cancer	8.63e-05	0.00106	CcSEcCtD
Irbesartan—Somnolence—Epirubicin—bone cancer	8.61e-05	0.00106	CcSEcCtD
Irbesartan—Anorexia—Doxorubicin—bone cancer	8.54e-05	0.00105	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—bone cancer	8.53e-05	0.00105	CcSEcCtD
Irbesartan—Dyspepsia—Epirubicin—bone cancer	8.52e-05	0.00105	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—bone cancer	8.46e-05	0.00104	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	8.45e-05	0.000982	CbGpPWpGaD
Irbesartan—Decreased appetite—Epirubicin—bone cancer	8.42e-05	0.00104	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—RGS1—bone cancer	8.38e-05	0.000974	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GRM4—bone cancer	8.38e-05	0.000974	CbGpPWpGaD
Irbesartan—Hypotension—Doxorubicin—bone cancer	8.37e-05	0.00103	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Epirubicin—bone cancer	8.36e-05	0.00103	CcSEcCtD
Irbesartan—Fatigue—Epirubicin—bone cancer	8.35e-05	0.00103	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—bone cancer	8.3e-05	0.000965	CbGpPWpGaD
Irbesartan—Pain—Epirubicin—bone cancer	8.28e-05	0.00102	CcSEcCtD
Irbesartan—Constipation—Epirubicin—bone cancer	8.28e-05	0.00102	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—bone cancer	8.22e-05	0.00101	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—bone cancer	8.18e-05	0.00101	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—bone cancer	8.18e-05	0.00101	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.16e-05	0.001	CcSEcCtD
Irbesartan—JUN—Apoptosis—TP53—bone cancer	8.14e-05	0.000947	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—EGFR—bone cancer	8.11e-05	0.000943	CbGpPWpGaD
Irbesartan—Paraesthesia—Doxorubicin—bone cancer	8.05e-05	0.00099	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—bone cancer	7.99e-05	0.000983	CcSEcCtD
Irbesartan—Feeling abnormal—Epirubicin—bone cancer	7.98e-05	0.000982	CcSEcCtD
Irbesartan—CYP1A2—Phase II conjugation—GSTP1—bone cancer	7.98e-05	0.000928	CbGpPWpGaD
Irbesartan—Somnolence—Doxorubicin—bone cancer	7.97e-05	0.00098	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—GNA11—bone cancer	7.93e-05	0.000921	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Epirubicin—bone cancer	7.92e-05	0.000974	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—IL3—bone cancer	7.91e-05	0.00092	CbGpPWpGaD
Irbesartan—Dyspepsia—Doxorubicin—bone cancer	7.89e-05	0.00097	CcSEcCtD
Irbesartan—CYP2C8—Biological oxidations—CYP3A4—bone cancer	7.85e-05	0.000912	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	7.82e-05	0.000909	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	7.8e-05	0.000907	CbGpPWpGaD
Irbesartan—Decreased appetite—Doxorubicin—bone cancer	7.79e-05	0.000958	CcSEcCtD
Irbesartan—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	7.74e-05	0.0009	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Doxorubicin—bone cancer	7.74e-05	0.000952	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—bone cancer	7.72e-05	0.00095	CcSEcCtD
Irbesartan—Urticaria—Epirubicin—bone cancer	7.69e-05	0.000946	CcSEcCtD
Irbesartan—Pain—Doxorubicin—bone cancer	7.66e-05	0.000943	CcSEcCtD
Irbesartan—Constipation—Doxorubicin—bone cancer	7.66e-05	0.000943	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—CDK4—bone cancer	7.66e-05	0.00089	CbGpPWpGaD
Irbesartan—Abdominal pain—Epirubicin—bone cancer	7.65e-05	0.000942	CcSEcCtD
Irbesartan—Body temperature increased—Epirubicin—bone cancer	7.65e-05	0.000942	CcSEcCtD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—bone cancer	7.64e-05	0.000888	CbGpPWpGaD
Irbesartan—Hypersensitivity—Methotrexate—bone cancer	7.62e-05	0.000938	CcSEcCtD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	7.6e-05	0.000884	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—MDM2—bone cancer	7.51e-05	0.000873	CbGpPWpGaD
Irbesartan—Asthenia—Methotrexate—bone cancer	7.42e-05	0.000913	CcSEcCtD
Irbesartan—Feeling abnormal—Doxorubicin—bone cancer	7.38e-05	0.000908	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	7.35e-05	0.000855	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Doxorubicin—bone cancer	7.33e-05	0.000901	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—bone cancer	7.32e-05	0.000901	CcSEcCtD
Irbesartan—PTGS1—Metabolism—NDUFA12—bone cancer	7.28e-05	0.000847	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GRM1—bone cancer	7.27e-05	0.000845	CbGpPWpGaD
Irbesartan—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	7.2e-05	0.000838	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL3—bone cancer	7.18e-05	0.000835	CbGpPWpGaD
Irbesartan—Hypersensitivity—Epirubicin—bone cancer	7.13e-05	0.000878	CcSEcCtD
Irbesartan—Urticaria—Doxorubicin—bone cancer	7.12e-05	0.000876	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	7.09e-05	0.000824	CbGpPWpGaD
Irbesartan—Body temperature increased—Doxorubicin—bone cancer	7.08e-05	0.000871	CcSEcCtD
Irbesartan—Abdominal pain—Doxorubicin—bone cancer	7.08e-05	0.000871	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—bone cancer	7.08e-05	0.000871	CcSEcCtD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—bone cancer	6.97e-05	0.00081	CbGpPWpGaD
Irbesartan—Asthenia—Epirubicin—bone cancer	6.95e-05	0.000855	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.94e-05	0.000807	CbGpPWpGaD
Irbesartan—Pruritus—Epirubicin—bone cancer	6.85e-05	0.000843	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—GNA11—bone cancer	6.85e-05	0.000796	CbGpPWpGaD
Irbesartan—Dizziness—Methotrexate—bone cancer	6.84e-05	0.000842	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—bone cancer	6.81e-05	0.000792	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—SMO—bone cancer	6.8e-05	0.000791	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—ATF1—bone cancer	6.78e-05	0.000788	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—GSTP1—bone cancer	6.71e-05	0.00078	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—RB1—bone cancer	6.66e-05	0.000774	CbGpPWpGaD
Irbesartan—Diarrhoea—Epirubicin—bone cancer	6.63e-05	0.000815	CcSEcCtD
Irbesartan—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	6.62e-05	0.000769	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—bone cancer	6.61e-05	0.000769	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—bone cancer	6.61e-05	0.000769	CbGpPWpGaD
Irbesartan—Hypersensitivity—Doxorubicin—bone cancer	6.6e-05	0.000812	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—bone cancer	6.58e-05	0.000809	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—RGS1—bone cancer	6.58e-05	0.000764	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GRM4—bone cancer	6.58e-05	0.000764	CbGpPWpGaD
Irbesartan—Rash—Methotrexate—bone cancer	6.52e-05	0.000803	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—bone cancer	6.52e-05	0.000802	CcSEcCtD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	6.5e-05	0.000755	CbGpPWpGaD
Irbesartan—Headache—Methotrexate—bone cancer	6.48e-05	0.000798	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—EGFR—bone cancer	6.44e-05	0.000749	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.44e-05	0.000749	CbGpPWpGaD
Irbesartan—Asthenia—Doxorubicin—bone cancer	6.43e-05	0.000791	CcSEcCtD
Irbesartan—Dizziness—Epirubicin—bone cancer	6.4e-05	0.000788	CcSEcCtD
Irbesartan—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.39e-05	0.000742	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.35e-05	0.000739	CbGpPWpGaD
Irbesartan—Pruritus—Doxorubicin—bone cancer	6.34e-05	0.00078	CcSEcCtD
Irbesartan—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	6.3e-05	0.000732	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	6.26e-05	0.000728	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—GNA11—bone cancer	6.22e-05	0.000723	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL3—bone cancer	6.21e-05	0.000722	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—bone cancer	6.16e-05	0.000716	CbGpPWpGaD
Irbesartan—Vomiting—Epirubicin—bone cancer	6.16e-05	0.000757	CcSEcCtD
Irbesartan—Nausea—Methotrexate—bone cancer	6.15e-05	0.000756	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—bone cancer	6.13e-05	0.000754	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	6.12e-05	0.000711	CbGpPWpGaD
Irbesartan—Rash—Epirubicin—bone cancer	6.11e-05	0.000751	CcSEcCtD
Irbesartan—Dermatitis—Epirubicin—bone cancer	6.1e-05	0.00075	CcSEcCtD
Irbesartan—Headache—Epirubicin—bone cancer	6.07e-05	0.000746	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—EGFR—bone cancer	6.07e-05	0.000705	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NT5C3A—bone cancer	6.03e-05	0.000701	CbGpPWpGaD
Irbesartan—Dizziness—Doxorubicin—bone cancer	5.92e-05	0.000729	CcSEcCtD
Irbesartan—Nausea—Epirubicin—bone cancer	5.75e-05	0.000708	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—EGFR—bone cancer	5.73e-05	0.000667	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GRM1—bone cancer	5.7e-05	0.000663	CbGpPWpGaD
Irbesartan—Vomiting—Doxorubicin—bone cancer	5.7e-05	0.000701	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—MDM2—bone cancer	5.68e-05	0.00066	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—bone cancer	5.67e-05	0.000659	CbGpPWpGaD
Irbesartan—Rash—Doxorubicin—bone cancer	5.65e-05	0.000695	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—bone cancer	5.64e-05	0.000694	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—IL3—bone cancer	5.64e-05	0.000656	CbGpPWpGaD
Irbesartan—Headache—Doxorubicin—bone cancer	5.61e-05	0.000691	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—EGFR—bone cancer	5.57e-05	0.000648	CbGpPWpGaD
Irbesartan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.56e-05	0.000646	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.51e-05	0.000641	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.46e-05	0.000635	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—CYP3A4—bone cancer	5.46e-05	0.000634	CbGpPWpGaD
Irbesartan—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.43e-05	0.000632	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—bone cancer	5.41e-05	0.000629	CbGpPWpGaD
Irbesartan—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.39e-05	0.000626	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	5.38e-05	0.000626	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	5.34e-05	0.000621	CbGpPWpGaD
Irbesartan—Nausea—Doxorubicin—bone cancer	5.32e-05	0.000655	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—SMO—bone cancer	5.12e-05	0.000595	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—bone cancer	5.09e-05	0.000592	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—bone cancer	5.05e-05	0.000587	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.03e-05	0.000584	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.92e-05	0.000572	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.92e-05	0.000572	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GRM4—bone cancer	4.91e-05	0.000571	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RGS1—bone cancer	4.91e-05	0.000571	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NDUFA12—bone cancer	4.7e-05	0.000547	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ENO2—bone cancer	4.69e-05	0.000546	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—GNA11—bone cancer	4.68e-05	0.000544	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—bone cancer	4.68e-05	0.000544	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.67e-05	0.000543	CbGpPWpGaD
Irbesartan—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.6e-05	0.000535	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—DHFR—bone cancer	4.35e-05	0.000506	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ATF1—bone cancer	4.35e-05	0.000506	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—bone cancer	4.31e-05	0.000501	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GRM1—bone cancer	4.26e-05	0.000495	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL3—bone cancer	4.24e-05	0.000493	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.22e-05	0.000491	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GNA11—bone cancer	4.07e-05	0.000473	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—bone cancer	4.05e-05	0.000471	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SMO—bone cancer	4.02e-05	0.000467	CbGpPWpGaD
Irbesartan—JUN—Immune System—ATF1—bone cancer	3.95e-05	0.000459	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NT5C3A—bone cancer	3.9e-05	0.000453	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NDUFA12—bone cancer	3.86e-05	0.000449	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KIT—bone cancer	3.86e-05	0.000448	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL3—bone cancer	3.85e-05	0.000447	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NDUFA12—bone cancer	3.83e-05	0.000445	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP3A4—bone cancer	3.69e-05	0.000429	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—GNA11—bone cancer	3.67e-05	0.000427	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFBR2—bone cancer	3.63e-05	0.000422	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.6e-05	0.000419	CbGpPWpGaD
Irbesartan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.55e-05	0.000413	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ATF1—bone cancer	3.42e-05	0.000397	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1R—bone cancer	3.42e-05	0.000397	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL3—bone cancer	3.33e-05	0.000387	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NDUFA12—bone cancer	3.27e-05	0.00038	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—bone cancer	3.26e-05	0.000379	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NT5C3A—bone cancer	3.2e-05	0.000372	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NT5C3A—bone cancer	3.17e-05	0.000369	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GSTP1—bone cancer	3.15e-05	0.000367	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MDM2—bone cancer	3.04e-05	0.000353	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SMO—bone cancer	3e-05	0.000349	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFBR2—bone cancer	2.85e-05	0.000331	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—GNA11—bone cancer	2.74e-05	0.000319	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NT5C3A—bone cancer	2.71e-05	0.000315	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1R—bone cancer	2.68e-05	0.000312	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO2—bone cancer	2.64e-05	0.000307	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ATF1—bone cancer	2.55e-05	0.000297	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NDUFA12—bone cancer	2.52e-05	0.000294	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL3—bone cancer	2.49e-05	0.000289	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KIT—bone cancer	2.48e-05	0.000288	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—DHFR—bone cancer	2.45e-05	0.000285	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—BRAF—bone cancer	2.33e-05	0.000271	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GNA11—bone cancer	2.29e-05	0.000266	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—bone cancer	2.26e-05	0.000262	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIT—bone cancer	2.25e-05	0.000261	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFBR2—bone cancer	2.13e-05	0.000247	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NT5C3A—bone cancer	2.09e-05	0.000243	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CYP3A4—bone cancer	2.08e-05	0.000242	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—bone cancer	2.08e-05	0.000241	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.07e-05	0.00024	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1R—bone cancer	2e-05	0.000233	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MDM2—bone cancer	1.95e-05	0.000227	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KIT—bone cancer	1.94e-05	0.000226	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—bone cancer	1.83e-05	0.000212	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GSTP1—bone cancer	1.78e-05	0.000207	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—bone cancer	1.77e-05	0.000206	CbGpPWpGaD
Irbesartan—JUN—Immune System—MDM2—bone cancer	1.77e-05	0.000206	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO2—bone cancer	1.71e-05	0.000198	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—JUN—bone cancer	1.7e-05	0.000197	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MMP9—bone cancer	1.65e-05	0.000192	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—bone cancer	1.63e-05	0.00019	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—DHFR—bone cancer	1.58e-05	0.000184	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MDM2—bone cancer	1.53e-05	0.000178	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GNA11—bone cancer	1.48e-05	0.000172	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—bone cancer	1.45e-05	0.000169	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO2—bone cancer	1.4e-05	0.000163	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—bone cancer	1.39e-05	0.000162	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—bone cancer	1.36e-05	0.000159	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP3A4—bone cancer	1.34e-05	0.000156	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.34e-05	0.000155	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—bone cancer	1.33e-05	0.000155	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—bone cancer	1.33e-05	0.000155	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—DHFR—bone cancer	1.3e-05	0.000151	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—bone cancer	1.29e-05	0.000151	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—DHFR—bone cancer	1.29e-05	0.00015	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GNA11—bone cancer	1.22e-05	0.000141	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—bone cancer	1.21e-05	0.000141	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GNA11—bone cancer	1.2e-05	0.00014	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—bone cancer	1.19e-05	0.000138	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTP1—bone cancer	1.15e-05	0.000133	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—bone cancer	1.14e-05	0.000133	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—bone cancer	1.12e-05	0.00013	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP3A4—bone cancer	1.1e-05	0.000128	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—DHFR—bone cancer	1.1e-05	0.000128	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP3A4—bone cancer	1.09e-05	0.000127	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.09e-05	0.000126	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—bone cancer	1.05e-05	0.000122	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GNA11—bone cancer	1.03e-05	0.00012	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—bone cancer	9.67e-06	0.000112	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTP1—bone cancer	9.42e-06	0.00011	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTP1—bone cancer	9.34e-06	0.000109	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP3A4—bone cancer	9.33e-06	0.000109	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.28e-06	0.000108	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—bone cancer	9.2e-06	0.000107	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—bone cancer	9.16e-06	0.000107	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—bone cancer	8.78e-06	0.000102	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—DHFR—bone cancer	8.5e-06	9.88e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTP1—bone cancer	7.98e-06	9.28e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GNA11—bone cancer	7.94e-06	9.24e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—bone cancer	7.82e-06	9.09e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—bone cancer	6.56e-06	7.63e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTP1—bone cancer	6.16e-06	7.16e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—bone cancer	5.95e-06	6.91e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—bone cancer	4.88e-06	5.67e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—bone cancer	4.84e-06	5.63e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—bone cancer	4.13e-06	4.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—bone cancer	3.19e-06	3.71e-05	CbGpPWpGaD
